Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 690-699

  Van De Berg, Pablo J ^a,b,c   Heutinck, Kirstin M ^a,b   Raabe, Robin ^b   Minnee, Robert C ^c   Young, Si La ^b   Van Donselaar Van Der Pant, Karlijn A ^a   Bemelman, Frederike J ^a   Van Lier, Rene A ^b   Ten Berge, Ineke J ^a  

^a Renal Transplant Unit   (United Kingdom)

^b Departments of Experimental Immunology   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; SERUM AMYLOID A;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; INFLAMMATION; KIDNEY TRANSPLANTATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; C-REACTIVE PROTEIN; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-18; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TH1 CELLS; VIRUS LATENCY;

EID: 77955686431     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655472     Document Type: Article

References (35)

1. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3:984-993.
2. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7(suppl 1):328-331.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917):868-874.
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15:199-207.
5. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129:550-564.
6. Essa S, Raghupathy R, Pacsa AS, El-Shazly A, Said T, Azizieh F. Th1- type cytokines production is decreased in kidney transplant recipients with active cytomegalovirus infection. J Med Virol 2000; 60:223-229.
7. Essa S, Pacsa A, Raghupathy R, et al. Low levels of Th1-type cytokines and increased levels of Th2-type cytokines in kidney transplant recipients with active cytomegalovirus infection. Transplant Proc 2009; 41: 1643-1647.
8. Nordoy I, Muller F, Nordal KP, et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000; 181:51-57.
9. Sadeghi M, Daniel V, Naujokat C, et al. Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation 2008; 86:275-285.
10. Rott D, Zhu J, Burnett MS, et al. Serum of cytomegalovirus-infected mice induces monocyte chemoattractant protein-1 expression by endothelial cells. J Infect Dis 2001; 184:1109-1113.
11. Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA. Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 1997; 185:1185-1192.
12. Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65:476-485.
13. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004; 65:486-492.
14. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim- van Dillen PM, van Lier RA. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173:1834-1841.
15. Gamadia LE, van Leeuwen EM, Remmerswaal EB, et al. The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. J Immunol 2004; 172:6107-6114.
16. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-385.
17. Boom R, Sol C, Weel J, Gerrits Y, de BM, Wertheim-Van DP. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J Clin Microbiol 1999; 37:1489-1497.
18. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101:2686-2692.
19. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL- 10. Nat Med 2009; 15:277-284.
20. Gabrysova L, Nicolson KS, Streeter HB, et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009; 206:1755-1767.
21. Apostolou I, Sarukhan A, Klein L, von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002; 3: 756-763.
22. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3:549-557.
23. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002; 16:755-758.
24. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007; 204:239-243.
25. Moore KW, O'Garra A, de Waal MR, Vieira P, Mosmann TR. Interleukin- 10. Annu Rev Immunol 1993; 11:165-190.
26. Libetta C, Sepe V, Zucchi M, et al. The effect of sirolimus- or cyclosporine- based immunosuppression effects on T-cell subsets in vivo. Kidney Int 2007; 72:114-120.
27. Daniel V, Naujokat C, Sadeghi M, Wiesel M, Hergesell O, Opelz G. Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation 2005; 79:1498-1506.
28. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-2115.
29. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2002; 2:539-549.
30. Homs S, Mansour H, Desvaux D, et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant 2009; 9:1230-1236.
31. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121:187-201.
32. Nilsson BO, Ernerudh J, Johansson B, et al. Morbidity does not influence the T-cell immune risk phenotype in the elderly: findings in the Swedish NONA Immune Study using sample selection protocols. Mech Ageing Dev 2003; 124:469-476.
33. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008; 325:397-415.
34. Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. Gammainterferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res 1988; 63:712-719.
35. Hansson GK, Libby P. The immune response in atherosclerosis: a double- edged sword. Nat Rev Immunol 2006; 6:508-519.